US protection ending in 2035: Infections
As of the edition of 20 October 2026, 23 drugs have US protection that ends in 2035 in infections; 11 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
23 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Bacillus anthracis protective antigen, adsorbed | Ends 2035 (computed from the first US licence) | Marketed | Emergent Product Development Gaithersburg, Inc. | 0 | |
| Bictegravir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Bimekizumab | Ends 2035 (computed from the first US licence) | Marketed | UCB | IL17A, IL17F | 2 |
| Brensocatib | Ends 2035 (patent) | Marketed | Insmed | CTSC | 1 |
| Cefiderocol | Ends 2035 (patent) | Marketed | Shionogi | 0 | |
| Chikungunya virus, live attenuated | Ends 2035 (computed from the first US licence) | Marketed | Valneva | 0 | |
| Danicopan | Ends 2035 (patent) | Marketed | AstraZeneca | CFD | 1 |
| Elranatamab | Ends 2035 (computed from the first US licence) | Marketed | Pfizer | CD3E, TNFRSF17 | 1 |
| Epcoritamab | Ends 2035 (computed from the first US licence) | Marketed | Merus | CD3D, CD3E, CD3G | 2 |
| Fruquintinib | Ends 2035 (patent) | Marketed | Takeda | FLT1, FLT4, KDR | 2 |
| Glecaprevir | Ends 2035 (patent) | Marketed | AbbVie | 0 | |
| Glofitamab | Ends 2035 (computed from the first US licence) | Marketed | Roche | CD3E, MS4A1 | 0 |
| Ibrexafungerp | Ends 2035 (patent) | Marketed | GSK | 0 | |
| Lenvatinib | Ends 2035 (patent) | Marketed | Eisai | FLT1, FLT4, KDR | 3 |
| Nirsevimab | Ends 2035 (computed from the first US licence) | Marketed | Sanofi | 0 | |
| Oritavancin | Ends 2035 (patent) | Marketed | Melinta Therapeutics | 0 | |
| Remdesivir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Respiratory syncytial virus pre-fusion glycoprotein f | Ends 2035 (reference-product exclusivity) | Marketed | GSK | 0 | |
| Retifanlimab | Ends 2035 (computed from the first US licence) | Marketed | Incyte | PDCD1 | 1 |
| Selinexor | Ends 2035 (patent) | Marketed | Karyopharm Therapeutics | XPO1 | 2 |
| Talquetamab | Ends 2035 (computed from the first US licence) | Marketed | Johnson & Johnson | CD3D, CD3E, CD3G | 1 |
| Toripalimab | Ends 2035 (computed from the first US licence) | Marketed | Coherus Oncology | PDCD1 | 2 |
| Zoliflodacin | Ends 2035 (exclusivity) | Marketed | Entasis Therapeutics | 0 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2035 in infections
In the product11 of these 23 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.